Critical Limb Ischemia
Conditions
Brief summary
Single-institution, prospective nonrandomized pilot study of critical limb ischemia patients with planned lower extremity revascularization will undergo Flowmet-D measurements in a wound care center setting to determine threshold values associated with wound healing and amputation. A subset of patients will undergo hyperbaric oxygen therapy and will have Flowmet-D measurements to determine those who respond best to therapy.
Detailed description
A single-institution, prospective nonrandomized pilot study will be conducted at Stanford Hospital and the Stanford Advanced Wound Care Center (AWCC). Patients with CLTI by WIfI criteria (ABI or toe pressures) and a concomitant non-healing lower extremity wound will be recruited. Inclusion criteria will include CLTI, at least one active lower extremity wound and planned lower extremity revascularization. ABI/TBIs will be recorded preintervention, post intervention and at one and three month intervals. Intraprocedural characteristics including the number and location of vessels revascularized, patent runoff vessels pre and post procedure, pedal arch anatomy and presence of angiographic blush to wound will be documented. Post-operatively, patients will be followed at the AWCC where they will receive standard of care wound management including offloading, regular debridement, infection and edema management. FlowMet-R perfusion values will be obtained prerevascularization, immediately post revascularization as well as weekly at each follow up AWCC visit for a total of up to 6 months or until wound healing.Wound size will be recorded. Patients who undergo hyperbaric oxygen therapy (at the discretion of AWCC surgeon) will have perfusion values performed before and after hyperbaric oxygen therapy sessions 1, 2, 10, 20, 30 and 40. Hyperbaric oxygen therapy will be conducted 5 days a week for duration of 90 minutes. Patients who undergo other advanced wound care treatments such as stem cell therapies or skin substitutes will also received FlowMet-R prior to and after treatment. Primary outcomes will be wound healing defined as complete skin epithelialization, wound improvement rate, major and minor amputations as well as need for repeat revascularization.
Interventions
DIAGNOSTIC_TESTFlowmet-D
Flowmet-D is a non-invasive device that measures blood flow.
DIAGNOSTIC_TESTABI
ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
Sponsors
Medtronic Endovascular
National Heart, Lung, and Blood Institute (NHLBI)
Stanford University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
CLI Cohort: * CLI by WIfI criteria (ABI or toe pressures) * Non-healing lower extremity wound * Planned lower extremity revascularization * Able to provide informed consent * Able to comply with study procedures HBO Cohort: * All of the above * Enrolled in HBO therapy post revascularization (at the discretion of the provider)
Exclusion criteria
* Under 30 * Wound not suitable for FlowMet-D probe attachment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Wound Healing | 6 months | Wound Healing, defined as complete skin epithelialization, will be associated with Flowmet-D measurements. |
| Wound Improvement | 6 months | Wound Improvement, defined as improvement in wound size, will be associated with Flowmet-D values. |
| Major Amputation | 6 months | Major amputation, defined as amputation above the ankle joint, will be associated with Flowmet-D values. |
| Minor Amputation | 6 months | Minor amputation, defined as amputation below the ankle joint, will be associated with Flowmet-D values. |
| Repeat Revascularization | 6 months | Repeat Revascularization, defined as unplanned repeat lower extremity revascularization, will be monitored. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response to Hyperbaric Oxygen Therapy | 6 months | Response to Hyperbaric Oxygen Therapy, will be defined as improved perfusion (improved Flowmet-D value) following therapy |
Countries
United States
Outcome results
None listed